지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2013.1
- 수록면
- 695 - 700 (6page)
이용수
초록· 키워드
오류제보하기
Despite recent findings of hepatic daidzein metabolites on prevention of skin and colon cancers, little study has been performed on breast cancer. In this study, we found that 6,7,4'-trihydroxyisoflavone, one of the major hepatic metabolite of the daidzein more significantly inhibited proliferation of MCF10CA1a human estrogen receptor (ER)-negative breast cancer cells, which was derived from arresting cell cycle at S- and G2/M phase. Cyclins and cyclin-dependent kinases (CDKs) involved in S- and G2/M phases, including cyclins A, B, E, CDK1 and CDK2 were regulated by 6,7,4'-trihydroxyisoflavone as well as CDK inhibitor, p21 and p27, in a dose-dependent manner. In addition, 6,7,4'-trihydroxyisoflavone induced apoptosis by enhancing death receptor4 (DR4) expression and suppressing the X-linked inhibitor of apoptosis protein, leading to poly ADP-ribose polymerase cleavage. Taken together, 6,7,4'-trihydroxyisoflavone inhibits cell proliferation via arresting cell cycle at S- and G2/M phases and inducing apoptosis in MCF10CA1a human breast cancer cells. These results suggest that the hepatic metabolite of daidzein, 6,7,4'-trihydroxyisoflavone, may be considered as a more potent agent in inhibiting ER-negative breast carcinogenesis.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청이 논문의 저자 정보
최근 본 자료
댓글(0)
0